BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Becker E, Dedden M, Gall C, Wiendl M, Ekici AB, Schulz-Kuhnt A, Schweda A, Voskens C, Hegazy A, Vitali F, Atreya R, Müller TM, Atreya I, Neurath MF, Zundler S. Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab. Gut 2021:gutjnl-2021-324868. [PMID: 34462337 DOI: 10.1136/gutjnl-2021-324868] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Zundler S, Günther C, Kremer AE, Zaiss MM, Rothhammer V, Neurath MF. Gut immune cell trafficking: inter-organ communication and immune-mediated inflammation. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35945456 DOI: 10.1038/s41575-022-00663-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Schweda A, Becker E, Wiendl M, Atreya R, Atreya I, Müller TM, Neurath MF, Zundler S. Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells. Inflamm Bowel Dis 2022:izac137. [PMID: 35815779 DOI: 10.1093/ibd/izac137] [Reference Citation Analysis]
3 Kotsiliti E. Integrin-based therapy in IBD. Nat Rev Gastroenterol Hepatol 2021;18:747. [PMID: 34556826 DOI: 10.1038/s41575-021-00526-1] [Reference Citation Analysis]
4 Adolph TE, Siegmund B. Deciphering the vedolizumab dosing conundrum in IBD: when less is more. Gut 2021:gutjnl-2021-325893. [PMID: 34497148 DOI: 10.1136/gutjnl-2021-325893] [Reference Citation Analysis]